20. The pharmaceutical composition according to any one of claims 13 to 19, wherein the compound of any one of claims 1 to 10 is associated with at least one therapeutically active anti-cancer agent.

21. The pharmaceutical composition according to any one of claims ~~1~~11 to 20 which is suitable for oral-, parenteral-, ocular-, transdermal-, nasal-administration, or for inhalation.

22. A pharmaceutical composition according to claims 13, wherein the nanoparticles comprise an item selected from PLGA nanoparticules, PLGA-PEG nanoparticles (block type AB, BA, ABA or BAB, where A = PLGA and B = PEG) and targeted nanoparticules

23. A pharmaceutical composition according to claims 22, wherein the nanoparticle is a targeted nanoparticle containing a signaling motif.

24. A pharmaceutical composition comprising a combination of a therapeutically effective amount of a compound according to any one of claims 1 to 10 and a therapeutically effective amount of one or more anti-neoplastic agents, wherein the components constituting said combination are for simultaneous, separate or sequential use in cancer therapy.

25. The pharmaceutical composition of claim 12 or claim 24, wherein the anti-neoplastic agent is selected from the group consisting of everolimus, chloroquine, hydroxychloroquine, trabectedin, abraxane, TLK 286, AV-299, DN-101, pazopanib, GSK690693, RTA 744, ON 0910.Na, AZD 6244 (ARRY-142886), AMN-107, TKI-258, GSK461364, AZD 1152, enzastaurin, vandetanib, ARQ-197, MK-0457, MLN8054, PHA-739358, R-763, AT-9263, pemetrexed, erlotinib. dasatanib, nilotinib, decatanib, panitumumab, amrubicin, oregovomab, Lep-etu, nolatrexed, azd2171, batabulin, ofatumumab, zanolimumab, edotecarin, tetrandrme, rubitecan, tesmilifene, oblimersen, ticilimumab, ipilimumab, gossypol, Bio 111, 131-I-TM-601, ALT-110, BIO 140, CC 8490, cilengitide, gimatecan. IL13-PE38QQR, TNO 1001, IPdR1 KRX-0402, lucanthone, LY 317615, neuradiab, vitespan, Rta 744, Sdx 102, talampanel, atrasentan,

28. A compound according to any one of claims 1 to 10, for use as a therapeutically active substance for the treatment and/or prevention of a proliferative and/or neoplastic disease.

29. A compound for use according to claim 28, wherein the proliferative and/or neoplastic disease is selected from the group consisting of: carcinoma; cancer of the esophagus, head, kidney, liver, lung, nasopharyngeal, neck, ovary, pancreas, prostate, or stomach; a leukemia (e.g. acute myelogenous leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia (APL), acute T-cell lymphoblastic leukemia, adult T-cell leukemia, basophilic leukemia, eosinophilic leukemia, granulocytic leukemia, hairy cell leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, neutrophilic leukemia and stem cell leukemia); a malignant lymphoma, a malignant melanoma; myeloproliferative diseases; a sarcoma; a tumor of the central nervous system; a germ-line tumor; testicular cancer; thyroid cancer; astrocytoma; colon cancer, melanoma, and a mixed type of neoplasia.

30. ~~A method for the treatment and/or prevention of a proliferative and/or neoplastic disease, comprising the step of administering a therapeutically active amount of a compound according to any one of claims 1 to 10, or a pharmaceutical composition according to any one of claims 11 to 26, to a human being or animal in need thereof.~~ A therapeutically active amount of a compound according to any one of claims 1 to 10, or a pharmaceutical composition according to any one of claims 11 to 26, for use as a therapeutically active substance for inhibiting the growth or differentiation of a Cancer Stem Cell (CSC), a tumor initiating cell, a mesenchymal-like cell associated with cancer, a mesenchymal cancerous cell, or a mesenchymal cell.

31. ~~A method for inhibiting the growth or differentiation of a Cancer Stem Cell (CSC), a tumor initiating cell, a mesenchymal-like cell associated with cancer, a mesenchymal cancerous cell, or a mesenchymal cell comprising the step of administering a therapeutically active amount of a compound according to any one of claims 1 to 10, or a pharmaceutical composition according to any one of claims 11 to 26, to a human being or an animal in need thereof.~~